Showing results (71-80 of 90) with videos related to

Sort By:
Pageof 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2018
Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth In VivoViktoria Laszlo, Zsuzsanna Valko, Ildiko Kovacs, et al.
Cells|September 19, 2019
Expression of FGFR1-4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor SensitivityGregor Vlacic, Mir A Hoda, Thomas Klikovits, et al.
Oncoimmunology|May 4, 2018
Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosisDiana Groza, Sebastian Gehrig, Pavol Kudela, et al.
Chemico-Biological Interactions|September 16, 2024
The tyrosine kinase inhibitor Nintedanib induces lysosomal dysfunctionality: Role of protonation-dependent crystallization processesElena Mosca, Anja Federa, Christine Pirker, et al.
Acta Neuropathologica Communications|August 9, 2019
TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAFV600E/TERT promoter double-mutated gliomaLisa Gabler, Daniela Lötsch, Dominik Kirchhofer, et al.
Histopathology|March 15, 2020
Comparative analysis of prognostic histopathologic parameters in subtypes of epithelioid pleural mesotheliomaAgnes Bilecz, Paul Stockhammer, Dirk Theegarten, et al.
Oncotarget|June 8, 2018
Altered membrane rigidity via enhanced endogenous cholesterol synthesis drives cancer cell resistance to destruxinsDaniela Heilos, Clemens Röhrl, Christine Pirker, et al.
Cancer Research|January 9, 2020
Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid FeaturesMiriam Marqués, Robin Tranchant, Blanca Risa-Ebrí, et al.
Journal of Medicinal Chemistry|February 24, 2024
Paraptotic Cell Death as an Unprecedented Mode of Action Observed for New Bipyridine-Silver(I) Compounds Bearing Phosphane ColigandsRicardo G Teixeira, Alessia Stefanelli, Adhan Pilon, et al.
American Journal of Respiratory and Critical Care Medicine|September 5, 2014
Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapyKarin Schelch, Mir A Hoda, Thomas Klikovits, et al.
Pageof 9